



(51) International Patent Classification:

A61K 47/68 (2017.01) **C07K 5/103** (2006.01)**A61P 35/00** (2006.01)

(21) International Application Number:

PCT/IB2023/055316

(22) International Filing Date:

23 May 2023 (23.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/345,286 24 May 2022 (24.05.2022) US

(71) Applicant: **DAIICHI SANKYO COMPANY, LIMITED** [JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP).(72) Inventors: **MCLEOD, Robert**; c/o Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, New Jersey 07920-2311 (US). **MYOBATAKE, Yusuke**; c/o Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, New Jersey 07920-2311 (US). **ISHIZAKA, Tomomichi**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **NISHIYA, Yumi**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **SAITO, Chiemmi**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **SUZUKI, Hirokazu**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **NAGASE, Shotaro**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **CRAVEIRO, Thuy Vu**; c/o Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, New Jersey 07920-2311 (US). **SUBRA-****MANIAN, Kulandayan**; c/o Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, New Jersey 07920-2311 (US). **LIN, Jie**; c/o Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, New Jersey 07920-2311 (US). **ASANO, Daigo**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP). **KELLERMANN HURTADO, Felipe**; c/o Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, New Jersey 07920-2311 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


(54) Title: DOSAGE REGIMEN OF AN ANTI-CDH6 ANTIBODY-DRUG CONJUGATE

Figure 1

Dose Escalation (Part A)

DS-6000a IV q3w

Histologically- or cytologically-documented locally advanced or metastatic RCC or high-grade serous OVC



(57) Abstract: The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-cadherin-6 (CDH6) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*